caa a22 4500 469117036 CHVBK 20180323133127.0 cr unu---uuuuu 170328e19921101xx s 000 0 eng 10.1007/BF00172601 doi (NATIONALLICENCE)springer-10.1007/BF00172601 Halperin Edward The CNS Cancer Consortium and the Department of Radiation Oncology, Duke University Medical Center, 27710, Durham, N. C., USA aut Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas [Elektronische Daten] [Edward Halperin] The prognosis following therapy for adults with supratentorial malignant gliomas is poor. Standard therapy of 60 Gy of external beam radiotherapy with chemotherapy achieves a median survival time of 35 to 51 weeks following surgery. A variety of innovative therapies have been considered for therapy of malignant gliomas. Multiple-fraction-per-day (MFD) external beam radiotherapy has been evaluated by many investigators. The rationale for MFD teletherapy is based upon exploiting differences in the recovery capacity for radiation damage between slowly and rapidly proliferating tissues and/or shortening the overall treatment time. A large number of clinical trials have, for the most part, failed to show any survival benefit from MFD radiotherapy. These trials have utilized b.i.d. and t.i.d. radiotherapy with fraction sizes of 0.89 to 2 Gy to total doses of 30-81.6 Gy. The linear quadratic model of the radiation cell survival curve suggests that a biological effective tumoricidal dose ≥ 10% higher than standard daily radiotherapy, with approximately isoeffective normal tissue damage, could be achieved at 1.2 Gy b.i.d. to a total dose of approximately 72 Gy. Trials of low dose per fraction MFD radiotherapy, to total doses less than 72 Gy, would be predicted to be inadequate to the task. Kluwer Academic Publishers, 1992 anaplastic astrocytomas nationallicence astrocytomas nationallicence brain neoplasms nationallicence glioblastoma multiforme, radiotherapy nationallicence Journal of Neuro-Oncology Kluwer Academic Publishers 14/3(1992-11-01), 255-262. 0167-594X 14:3<255 1992 14 11060 https://doi.org/10.1007/BF00172601 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172601 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Halperin Edward The CNS Cancer Consortium and the Department of Radiation Oncology, Duke University Medical Center, 27710, Durham, N. C., USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 14/3(1992-11-01), 255-262 0167-594X 14:3<255 1992 14 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer